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SMAR1 binds to T(C/G) repeat 
and inhibits tumor progression by 
regulating miR-371-373 cluster
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Chromatin architecture and dynamics are regulated by various histone and non-histone proteins. The 
matrix attachment region binding proteins (MARBPs) play a central role in chromatin organization and 
function through numerous regulatory proteins. In the present study, we demonstrate that nuclear 
matrix protein SMAR1 orchestrates global gene regulation as determined by massively parallel ChIP-
sequencing. The study revealed that SMAR1 binds to T(C/G) repeat and targets genes involved in diverse 
biological pathways. We observe that SMAR1 binds and targets distinctly different genes based on the 
availability of p53. Our data suggest that SMAR1 binds and regulates one of the imperative microRNA 
clusters in cancer and metastasis, miR-371-373. It negatively regulates miR-371-373 transcription as 
confirmed by SMAR1 overexpression and knockdown studies. Further, deletion studies indicate that 
a ~200 bp region in the miR-371-373 promoter is necessary for SMAR1 binding and transcriptional 
repression. Recruitment of HDAC1/mSin3A complex by SMAR1, concomitant with alteration of histone 
marks results in downregulation of the miRNA cluster. The regulation of miR-371-373 by SMAR1 inhibits 
breast cancer tumorigenesis and metastasis as determined by in vivo experiments. Overall, our study 
highlights the binding of SMAR1 to T(C/G) repeat and its role in cancer through miR-371-373.
The nuclear matrix is an intricate yet dynamic platform composed of two interacting partners, i.e., nucleic acids 
and proteins. It not only serves as a hub of vital cellular events such as replication, transcription and transcription 
coupled alternative splicing; but also provides a niche for DNA damage repair and recombination1. Among the 
different factors involved in compaction and tethering of chromatin to the nuclear matrix, the class of S/MAR 
binding proteins (MARBPs) play crucial role. DNase I hypersensitive sites, known as S/MARs (Scaffold/Matrix 
Attachment binding regions), often situated in close proximity to promoters and enhancers are the regions to 
which these MARBPs bind2. They work in a consorted fashion with co-activator or co-repressor complexes at 
MARs, thereby remodeling the chromatin and regulating gene expression in a tissue and context-dependent 
manner.
SMAR1 (Scaffold/Matrix Attachment region 1), one such MARBP, identified from double positive mouse 
thymocytes, is reported principally to be a transcriptional regulator. Subsequently, SMAR1 is known to interact 
with p53 and act as tumor suppressor resulting in tumor regression in vivo3. SMAR1 inhibits CyclinD1 transcrip-
tion by recruiting the mSin3A/HDAC1 repressor complex to its promoter4. Interestingly, it has been observed 
that as the grades of breast carcinoma progress, the levels of SMAR1 reduce significantly5. It also plays a decisive 
role in the fate of a cell, in order to decide between cell cycle arrest and apoptosis, by modulating its interac-
tion with p536. Therefore, investigating SMAR1 target genes (both protein coding and non-coding) in a high 
throughput manner and its dependency on tumor suppressor protein p53 was a lucrative objective that has been 
addressed in the present work. Massively parallel high throughput ChIP sequencing for SMAR1 was carried out 
in HCT116 p53+/+ and HCT116 p53−/− cell lines to address this objective. A repeat sequence was identified and 
validated as the binding site of SMAR1. The predicted SMAR1 targets, including microRNAs, were validated and 
categorized into different biological pathways.
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MicroRNAs (miRNAs) are endogenous, evolutionarily conserved, small noncoding RNAs that control 
post-transcriptional gene regulation7. Conventionally they bind to the 3′ UTR of their target mRNAs through 
an imperfect match, thereby suppressing their translation and stability8; however, reports suggest that miRs can 
bind to gene promoters enhancing gene transcription9. As single miRNA can regulate a large number of target 
genes which lie across diverse biological pathways, miRNAs can dictate and control multiple biological processes, 
including pluripotency, apoptosis, differentiation, development, and diseases including cancer10,11. MicroRNAs 
can either act as tumor suppressors, viz., let-7, miR-16-1 and miR-15a or behave like oncogenes (oncomiRs), for 
example miR-17~92, miR-155, miR-372 and miR-37312. Although the mechanisms by which miRNAs regulate 
the expression of their targets are well documented, factors regulating genesis of miRNAs remain largely unad-
dressed. Interestingly, many miRNA gene(s) occur in clusters, indicating that they might be regulated by common 
transcription factors in an all or none fashion. Various MAR binding proteins in association with other transcrip-
tion factors have been shown to regulate gene clusters at large distance through locus control regions (LCRs)13,14. 
Hence we sought to understand the transcriptional regulation of microRNA target genes by SMAR1. Preliminary 
studies from our lab have suggested that SMAR1 can potentially regulate the expression of numerous microR-
NAs vital for different physiological processes. MicroRNA-microarray analysis upon SMAR1 over expression and 
knockdown in HCT116 p53+/+ cells identified microRNAs essential for erythropoiesis, pluripotency of stem cells, 
apoptosis, cell cycle and tumorigenesis (Supplementary Fig. S1). One such interesting cluster of miRNAs impor-
tant in stem cell pluripotency and cancer progression is the miR-371-373 cluster. In this study we have aimed to 
establish the transcriptional regulation of this microRNA cluster by the nuclear matrix protein SMAR1 in the 
context of breast cancer tumorigenesis and metastasis. Thus, we have focused on the role of SMAR1 as a global 
gene regulator involved in multiple biological pathways, and as a tumor suppressor protein via transcriptional 
repression of the miR-371-373 cluster.
Results
Mapping the genome-wide distribution of the nuclear matrix protein SMAR1. As SMAR1 can 
alter the function of p53 in response to the severity of DNA damage and differentially drive the cell towards cell 
cycle arrest or apoptosis6, its role as a critical transcriptional switch becomes undisputed. Thus, the dynamic inter-
actions between p53 and SMAR1 can vary the outcome of gene expression significantly and thereby the fate of the 
cell. Therefore, in order to identify genome-wide targets of SMAR1, chromatin immunoprecipitation combined 
with massively parallel sequencing (ChIP-Seq) was performed for the nuclear matrix protein SMAR1 using chro-
matin prepared from HCT116 p53+/+ and HCT116 p53−/− pull down samples. The α -SMAR1 antibody used for 
ChIP was first validated using immunoblotting assays and the ChIP DNA samples prepared using α -SMAR1 anti-
body were analyzed for presence of known SMAR1 target gene sequence like Cyclin D1 (Supplementary Fig. S2). 
After such confirmation, the DNA samples were subjected to high-throughput sequencing and the sequence data 
obtained was subjected to the ChIP-seq data processing pipeline using in silico tools. The bowtie alignment sta-
tistics is shown in Supplementary Table S3. The data discussed in this publication (raw and processed files) have 
been submitted to National Center for Biotechnology Information- Gene Expression Omnibus (NCBI-GEO) 
and are accessible through GEO Series accession number GSE70058 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE70058). The SMAR1 peak coordinates and their gene annotations for both datasets have been 
provided in Supplementary spreadsheet 1. Detailed visualization of individual peak region for few genes has been 
shown in Supplementary Fig. S3.
In silico comparison of SMAR1 binding peaks in HCT116 p53+/+ and HCT116 p53−/− data sets. 
SMAR1 functions by recruiting co-repressor complex to gene promoter or gene body for regulation of transcrip-
tion, transcription-coupled splicing, DNA damage repair and other vital cellular functions. Hence, we planned to 
determine the genome-wide binding pattern of SMAR1 and correlate it with transcription. The analysis suggested 
that SMAR1 has a diverse binding pattern with respect to different gene components. Approximately, 29% of 
SMAR1 binding was observed in the promoter regions and regulatory elements (5′ UTR and first introns) of the 
gene in both the data sets. Around 53% of SMAR1 binding was detected within the gene body irrespective of the 
data set (Fig. 1A).
Further, in order to ascertain the binding pattern of SMAR1 influencing nearest gene, the fold enrichment of 
SMAR1 peaks within − 5 and + 5 kb of TSS was determined. The genes having SMAR1 peaks within − 5 to 0 kb of 
their TSSs are henceforth termed as downstream target genes. The results revealed that SMAR1 has the highest 
predisposition to bind upstream of the TSS, i.e., within − 1 to 0 kb, which represents the promoter region of the 
gene. The percent binding of SMAR1 in the promoter region was ~6% in HCT116 p53+/+ data set, while ~9% in 
the HCT116 p53−/− data set (Fig. 1B). The SMAR1 binding was observed to decrease as the distance from the TSS 
increases. Thus, we found that SMAR1 binds to several components of gene across the chromosomes, but has an 
enriched occupancy at the gene promoters.
SMAR1 binds distinct genes depending on p53 status. As SMAR1 and p53 are known to interact and 
associate with each other, they might regulate downstream target genes either independently or in a co-operative 
fashion. In order to identify novel target genes regulated by SMAR1 in presence and absence of p53, the data sets 
for HCT116 p53+/+ and HCT116 p53−/− were analyzed and compared for common gene targets using in-house 
custom Perl scripts. This analysis revealed a total of 1876 genes, which are common to both the data sets, indicat-
ing that these gene regions are occupied by SMAR1 irrespective of the p53 status. Also, it was observed that 5617 
SMAR1 gene targets were unique to the HCT116 p53+/+ data set, signifying their regulation might be dependent 
on the p53 status. Furthermore, about 8198 gene targets were found to be bound by SMAR1 only in absence of 
p53, suggesting p53 independent regulation of these genes by SMAR1 (Fig. 1C). Thus, the SMAR1 gene targets 
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can be categorized on the basis of this analysis into three groups: p53 wild type unique (5617 genes), p53 null 
unique (8198) and common genes (1876). Hence, we conclude that SMAR1 binds and might regulate distinct 
subsets of genes depending on the availability of p53.
SMAR1 binds to a T(C/G) repeat DNA. In order to determine whether SMAR1 recognizes a particular 
DNA sequence as its binding site, the sequences corresponding to all peak co-ordinates were retrieved from the 
UCSC genome browser. The sequences thus obtained were analyzed for the presence of a consensus sequence 
using MEME-ChIP v4.10.1. The motif search revealed that a dinucleotide T(C/G) repeat sequence was enriched 
in sequences corresponding to peaks (E-value 1.4e−2329) (Fig. 2A). The distribution of length and frequency of 
occurrence of repeats has been shown in Supplementary Fig. S4. In order to validate the affinity of SMAR1 to 
this DNA sequence, we carried out an isothermal titration calorimetry to confirm the specificity of interac-
tion between SMAR1 and its T(C/G) DNA binding repeat. The data indicated a linear correlation between the 
two with increasing amounts of oligo and SMAR1 protein, accompanied with a significant Δ H value (Fig. 2B). 
We carried out competitive electrophoretic mobility shift assay to further validate this interaction. The results 
showed a significant increase in SMAR1 binding to both fluorescently tagged oligos in a dose-dependent manner. 
It was also observed that only (TC)10 and (TG)10 could compete for binding to SMAR1 protein. The presence 
of any other untagged, dinucleotide oligos in the reaction mixture did not inhibit the binding of SMAR1 to the 
fluorophore-tagged oligos (Fig. 2C,D). These results indicate that SMAR1 prefers a dinucleotide T(C/G) DNA 
repeat sequence for accessing chromatin to exert its regulatory effects.
SMAR1 binds to gene targets across varied biological pathways. As this study was the first of its 
kind to unravel novel and global gene targets of SMAR1, we were interested in understanding the diverse roles 
of SMAR1 via control of different downstream target genes. The SMAR1 gene targets in both the data sets as 
predicted by ChIP-seq analysis were subjected to DAVID Functional Annotation tools15. The target genes were 
then broadly classified into functional categories and selected for critical analysis. The DAVID functional analysis 
suggested that the SMAR1 gene targets in both the data sets belonged to a broad range of biological processes, viz., 
splicing, protein and histidine metabolism, pulmonary disorders, viral infection, insulin and calcium signalling, 
3′ UTR mediated translation regulation, cancer and metastasis, etc. (Fig. 3A,B). A distinct category of microRNA 
and long non-coding RNA (lncRNA) genes were also predicted to be targeted by SMAR1 (Supplementary Fig. S5).
A number of microRNAs, viz., miR-205, miR-383, miR-572, miR-371-373, miR-100, miR-32, miR-206, miR-
147, miR-221/222, etc. playing diverse roles in cancer cell proliferation and metastasis, differentiation, epithelial 
to mesenchymal transition (EMT), inflammation and many other vital cellular functions have been predicted to 
be SMAR1 targets by ChIP-seq analysis16–24. Thus, our data suggests multi-faceted role of SMAR1 and projects 
new and unexplored pathways that SMAR1 might orchestrate globally.
SMAR1 and p53 bind and regulate target genes in a competitive manner. Tumor suppressor 
p53 is reported to recognize a 10 bp consensus DNA motif sequence 5′ -PuPuPuC(A/T)(T/A)GPyPyPy-3′ 25. As 
SMAR1 is known to associate with p53 and mediate regulation of downstream gene targets6,26, we were interested 
to check for the presence of p53 binding site in the vicinity of SMAR1 binding repeat sequence. In order to address 
this objective, we scanned for the presence of the canonical p53 motif within 50 bp upstream and downstream of 
Figure 1. Mapping genome-wide distribution of the nuclear matrix protein SMAR1. (A) Distribution of 
SMAR1-binding sites within specific gene components as analyzed by the Nearest Downstream Gene (NDG) 
function of PeakAnalyzer software in HCT116 p53+/+ and HCT116 p53−/−cell lines. (B) The percentage of SMAR1 
bound peaks within ± 5 kb of Transcription Start Site (TSS) for all gene targets in HCT116 p53+/+ and HCT116 
p53−/−cell lines. (C) Comparison of SMAR1 gene targets from HCT116 p53+/+ and HCT116 p53−/− data sets.
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peak co-ordinates in the HCT116 p53+/+ data set and selected such gene targets for further study27. Of the genes 
that harbour both SMAR1 and p53 binding sites in their promoters, 8 genes (including lncRNAs and miRNA) 
were selected randomly (Supplementary Table S1) and subjected to chromatin immunoprecipitation in HCT116 
p53+/+ and HCT116 p53−/− cell lines. The real-time PCR analysis suggested specific binding of p53 in these gene 
promoters while SMAR1 occupancy was found to be diminished at these regions in HCT116 p53+/+ cell line 
(Fig. 3C,D). However, in absence of p53 in HCT116 p53−/− cell line, SMAR1 was observed to be enriched at these 
gene promoters (Fig. 3E), suggesting a competitive binding of SMAR1 and p53 at these gene promoters.
Further, we elucidated the effect of SMAR1 occupancy in the regulation of these gene targets, by overexpres-
sion and knockdown of SMAR1. As SMAR1 generally mediates gene repression, we wanted to determine the 
transcript levels of these genes in HCT116 p53+/+ and HCT116 p53−/− cell lines. Overexpression and knockdown 
of SMAR1 in HCT116 p53+/+ cells did not correlate inversely with the gene transcript levels (Fig. 3F). In these 
cells, the genes RP11-271C24.2, RP11-419C23.1 and LILRB did not show significant change either upon SMAR1 
overexpression or downregulation. TRAV21, U6, CLINT1 and miR-373 showed elevated levels irrespective of 
SMAR1 overexpression or knockdown. The Y RNA gene exhibited induced transcription upon Adeno-SM treat-
ment but remains unaltered upon SMAR1 knockdown by sh1077 construct. However, in HCT116 p53−/− cell line, 
SMAR1 overexpression reduced the gene transcription and knockdown of SMAR1 considerably increased all the 
gene transcripts as detected by real time PCR (Fig. 3G). As we observed reduced expression levels of miR-373 in 
HCT116 cell lines, due to its epigenetic silencing28, we determined the miR-373 expression across various cancer 
cell lines (Supplementary Fig. S6). We observed that miR-373 expression was significant in breast cancer lines. 
Hence, we have used breast cancer as our model system for studying regulation of miR-373. Thus, we conclude 
that SMAR1 and p53 compete with each other for gene promoter occupancy as well as gene regulation.
SMAR1 binds and recruits repressor complex upstream of miR-371-373 cluster. In addition to 
the potential protein coding gene targets of SMAR1, a number of microRNAs were also predicted. As previously 
demonstrated, one of the microRNAs miR-373, showed p53-independent regulation by SMAR1. miR-371-373 
has been shown to play a central role in tumor progression as well as maintenance of stem cell pluripotency16,29. 
Hence, we sought to elucidate the role of SMAR1 in the regulation of miR-371-373 in breast cancer tumorigen-
esis and metastasis. The ChIP-seq analysis predicted the binding of SMAR1 to a region upstream of miR-371, 
which is the first miRNA of the miR-371-373 cluster and the peak was only observed in HCT116 p53−/− cells 
while it was absent in HCT116 p53+/+ cells (Fig. 4A). The MAR-Wiz (http://genomecluster.secs.oakland.edu/
MarWiz/) analysis performed in this region showed a significant MAR potential, further projecting the proba-
bility of MAR-binding proteins like SMAR1 to bind to this sequence (Fig. 4B). Next, we performed chromatin 
immunoprecipitation using α -SMAR1 antibody and the eluted DNA was amplified using primers spanning this 
Figure 2. SMAR1 binds to T(C/G) repeat DNA sequence. (A) The dinucleotide T(C/G) DNA sequence 
predicted by the MEME suite as SMAR1 binding motif. (B) Isothermal titration calorimetry (ITC) was performed 
with SMAR1 protein (the macromolecule) and increasing amounts of (TG)10 sequence oligo (the ligand).  
(C) Fluorescent electrophoretic mobility shift assay (EMSA) performed using Cy5 tagged motif oligos (TG)10 and 
(TC)10 in combination with other competitive non-fluorophore tagged oligos (AT)10, (GC)10, (TCTG)5, (TG)10 
and (TC)10 along with purified recombinant SMAR1 protein and poly (dI-dC). All the gels are run under same 
experimental condition. (D) The densitometry analysis of the supershift bands of interest of Fig. 2C.
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predicted SMAR1 binding region. The ChIP-PCR showed specific amplification in the immune pulled fraction, 
thus confirming the occupancy of SMAR1 at the miR-371-373 locus and validating the ChIP-seq data (Fig. 4C).
Taking into consideration the role of this miRNA cluster in cancer progression and metastasis, we were 
interested in understanding the role of SMAR1 in the transcriptional control of the microRNA cluster 371-373 
in different breast cancer cell lines. Therefore, we chose different grades of breast cancer cell lines for further 
experimentation. HEK293 was taken as a representative of normal, non-cancerous cells; MCF-7 represented the 
non-metastatic breast cancer, while MDA-MB-231 and T47D were representative of metastatic breast cancer. 
We were then interested in determining the presence of other activator/repressor factors bound in association 
with SMAR1. It was found that SMAR1 was significantly enriched at the miR-371-373 promoter region in both 
HEK293 and MCF-7 cell lines. The binding of SMAR1 in these cell lines was associated with the recruitment of 
co-repressor molecules HDAC1/mSin3A, while the decreased occupancy of SMAR1 in MDA-MB-231 and T47D 
cell lines revealed a subsequent decrease in the enrichment of these co-repressor factors as well. Interestingly, the 
repressive histone mark H3K9me3 that was abundant in HEK293 and MCF-7 cells, was also found to be reduced 
at the miR-371 promoter in metastatic cell lines MDA-MB-231 and T47D (Fig. 4D). On the other hand, presence 
of RNA polymerase II and the activation histone mark H3K9Ac was enriched at this region in the metastatic 
breast cancer lines as compared to the non-metastatic ones (Fig. 4E,F). These data indicated that SMAR1 recruits 
co-repressor molecules HDAC1/mSin3A resulting in local chromatin condensation in this region. Absence of 
SMAR1 at the miR-371 promoter resulted in recruitment of activation marks in this region. We also confirmed 
SMAR1 binding upstream of the miR-371-373 cluster by electrophoretic mobility shift assay (EMSA). These 
assays were performed using the PCR amplified miR-371-373 upstream region as the template, against increasing 
concentrations of purified, recombinant SMAR1 protein. The results showed a specific binding of SMAR1 to the 
template DNA, resulting in a shift in the mobility of the complex as compared to the free probe. Further, a dose 
dependent increase was observed in the intensity of the SMAR1-template complex (Fig. 4G). This result depicted 
the specificity of SMAR1 binding to the miR-371-373 promoter.
Figure 3. SMAR1 binds and targets distinct genes from various biological pathways depending on p53 
status. (A) Functional categorization of SMAR1 target genes using DAVID Functional Annotation tool in 
HCT116 p53+/+ data set and (B) HCT116 p53−/− data set. (C) The gene promoters with p53 binding motif in 
juxtaposition of SMAR1 binding peaks were amplified in chromatin immunoprecipitate of HCT116 p53+/+ by 
anti-p53 antibody and (D) anti-SMAR1 antibody. For convenience, RP11-271C24.2 and RP11-419C23.1 have 
been labeled as C24.2 and C23.1 respectively. (E) The gene promoters with p53 binding motif in juxtaposition 
of SMAR1 binding peaks were amplified in chromatin immunoprecipitate of HCT116 p53−/− by anti-SMAR1 
antibody. (F) Quantitative real-time PCR analysis of these gene targets upon overexpression and knockdown 
of SMAR1 in HCT116 p53+/+ cell line. (G) Quantitative real-time PCR analysis of these gene targets upon 
overexpression and knockdown of SMAR1 in HCT116 p53−/− cell line.
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To strengthen this observation, luciferase assays were performed using pluc371 and pluc371Δ MAR con-
structs (Fig. 4H). We observed that upon ectopic expression of SMAR1 in presence of the pluc371 vector there 
was decrease in luciferase activity, while SMAR1 knockdown increased the luciferase activity of the pluc371vec-
tor. This suggested and reconfirmed the recruitment of SMAR1 at the miR-371 promoter sequence. Additionally, 
there was negligible change in luciferase activities of the pluc371Δ MAR construct upon SMAR1 overexpression 
or knockdown (Fig. 4I). Thus, we concluded that there is specific interaction and recruitment of SMAR1 to the 
promoter of miR-371-373 cluster. This finding further led us to speculate the possible role of SMAR1 in the reg-
ulation of this cluster.
SMAR1 negatively regulates the transcription of miR-371-373. As the cell lines HEK293, MCF-7, 
MDA-MB-231 and T47D have an inherent difference in their metastasis potential, we wanted to estimate the 
endogenous levels of SMAR1 and miR-371-373 transcripts in these lines. We observed that endogenous SMAR1 
transcript and protein levels significantly decreased in the metastatic lines as compared to the non-metastatic 
ones, suggesting a negative correlation (Fig. 5A (i) and (ii)). The quantitative PCR analysis of the miR-371-373 
transcripts indicated that the levels of miR-371-373 significantly increase with the metastatic ability of the breast 
cancer cell line (Fig. 5B). Thus, HEK293 which represented the normal cells showed the least expression of these 
miR transcripts endogenously and the maximum SMAR1 expression. On the other hand, the metastatic lines 
MDA-MB-231 and T47D showed the maximum expression of the miR-371-373 transcripts, with T47D showing 
the highest expression. We next wanted to determine the effect of SMAR1 on the transcription of the microRNAs 
in this cluster. It was observed that the transcript levels of miR-371-373 cluster were drastically reduced upon 
Figure 4. SMAR1 binds and recruits repressor complex upstream of miR-371-373 cluster. (A) Peak 
visualization of ChIP-seq predicted binding of SMAR1 at miR-371-373 promoter in HCT116 p53+/+ and 
HCT116 p53−/− cells. (B) MAR-Wiz analysis for the miR-371-373 promoter showing presence of a potential 
MAR. X-axis denotes base pairs and Y-axis denotes MAR potential. (C) Chromatin immunoprecipitation 
(ChIP) was performed in MCF-7 cells by α -SMAR1 antibody using miR-371-373 promoter specific primers. 
Rabbit IgG was used as a control. Gel image shown here is the cropped version of whole gel image given 
in Supplementary Fig. S7. (D) ChIP followed by quantitative real time PCR (qRT PCR) was performed for 
detecting enrichment of SMAR1, mSin3A, HDAC1 and H3K9me3 at the miR-371-373 promoter in four 
cell lines, HEK293, MCF-7, MDA-MB-231 and T47D. (E) ChIP followed by quantitative real time PCR was 
performed for detecting enrichment of RNA polymerase II at the miR-371-373 promoter in all four cell lines. 
(F) The presence of histone active mark H3K9Ac was detected by ChIP-qRT PCR at the miR-371-373 promoter 
in all four cell lines. (G) Electrophoretic mobility shift assay (EMSA) performed for determining the presence 
of SMAR1 binding upstream of the miR-371-373 cluster. (H) Diagrammatic representation of pluc371 and 
pluc371Δ MAR constructs. (I) Relative luciferase activity of pluc371 and pluc371Δ MAR constructs upon 
ectopic expression and knockdown of SMAR1 as compared to control.
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Figure 5. SMAR1 negatively regulates the transcription of the miR-371-373 cluster. (A) (i) Endogenous 
transcript and (ii) protein levels of SMAR1 detected in the four cell lines HEK293, MCF-7, MDA-MB-231 and 
T47D by quantitative real time PCR and western blot, respectively. (B) Quantitative PCR analysis to detect 
endogenous miR-371-373 transcript levels in these four cell lines. (C) Reduced levels of miR-371-373 transcripts 
upon ectopic expression of SMAR1 using Adeno-SM as determined by quantitative real time PCR in all four cell 
lines. Empty adenoviral vector (Ad-V) was used as control. (D) Upregulation of miR-371-373 transcript levels 
upon SMAR1 knockdown using sh1077 construct observed in four cell lines by quantitative real time PCR. shRNA 
construct was used as control. (E) Ectopic SMAR1 expression and knockdown was confirmed at transcript levels 
in HEK293, MCF-7, MDA-MB-231 and T47D by quantitative real time PCR. (F) SMAR1 overexpression and 
knockdown was confirmed at protein levels in HEK293, MCF-7, MDA-MB-231 and T47D by western blot assay. 
All the western blots are cropped representation of the original blots shown in Supplementary Fig. S8. All the gels 
are run under same experimental conditions.
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ectopic expression of SMAR1 in all the four cell lines (Fig. 5C). The knock down of SMAR1 was found to reverse 
this effect resulting in increased levels of these transcripts (Fig. 5D). Overexpression and knock down of SMAR1 
was confirmed by quantitative real time PCR as well as immunoblot assays (Fig. 5E,F). Thus these results together 
indicate that SMAR1 regulates the expression of miR-371-373, transcriptionally.
SMAR1 inhibits cancer cell migration and invasion by regulating miR-371-373 cluster. In 
order to establish the biological relevance of SMAR1 binding and repressing an important cluster of microR-
NAs reported to have a role in tumorigenesis and metastasis, we studied the role of SMAR1 in cell migration by 
wound healing experiment. MDA-MB-231 control and Adeno-SMAR1 transduced confluent cell monolayers 
were subjected to a wound and time lapse assay was performed to check for cell migration and wound healing. 
In comparison to the control cells, the SMAR1 overexpressed cells showed significantly retarded cell migration 
and wound healing (Fig. 6A (i) and (ii)). Next, we compared the cell invasion ability of control MDA-MB-231 
cells against different treatments of SMAR1 and miR-371-373 overexpression and/or knockdown alone and 
in combination (Fig. 6B). It was observed that over expression of SMAR1 severely compromised the invasive 
capacity of these cells, while SMAR1 knockdown led to an increased invasiveness. The ectopic expression of 
miR-371, miR-372 and miR-373 enhanced cell invasion, and their respective antagomiRs inhibited it signifi-
cantly. Over expression of miR-371, 372 and 373 along with Adeno-SMAR1 surpassed the inhibitory effects of 
SMAR1, making cells as invasive as the control. Similarly, the use of antagomiRs along with SMAR1 knockdown, 
compensated for the enhanced cell invasion potential, now making it comparable or less invasive than control 
MDA-MB-231 cells. Similarly, the in vivo tumorigenicity and metastasis experiments in SCID mice using control 
and Adeno-SMAR1 transduced MDA-MB-231/Luc cells indicated a perturbed metastases in the mice injected 
with SMAR1 overexpressed cells, while the control mice showed metastatic foci (Fig. 6C). Infiltration and metas-
tasis of cells, accompanied by severe alveolar collapse is evident from the Hematoxylin and Eosin staining of 
the lung sections of control mice, while the Adeno-SMAR1 treated mice showed comparably normal lung and 
alveolar architecture (Fig. 6D). Quantitative real time PCR confirmed the increased levels of SMAR1 in the lung 
tissues of Adeno-SMAR1 treated mice (Fig. 6E). Parallely, we detected severely diminished levels of miR-371-373 
transcripts in these lung tissues (Fig. 6F).
To extrapolate and confirm our findings, we utilized the Kaplan-Meier plotter for breast cancer model. The 
Kaplan Meier plotter is a tool capable of assessing the effect of 22,277 genes on survival using 10,188 cancer sam-
ples, of which 4,142 are breast cancer samples with a mean follow-up of 69 months30. We performed the survival 
analysis on 1660 relapse free survival (RFS) breast cancer patient data with respect to SMAR1 expression levels. 
The KM plot for SMAR1 established that lower expression levels of SMAR1 correlated with poor prognosis and 
survival (Fig. 6G). Next, we wanted to determine the expression pattern of miR-371-373 cluster in breast cancer 
patients and their survival. We exploited the MIRUMIR online survival analysis tool which utilizes multiple 
clinical data sets to derive information on microRNAs as biomarkers in cancers31,32. The survival analyses for 
miR-371-5p and miR-373 revealed that higher expression levels of these microRNAs in breast cancer directly 
associated with lesser patient disease free survival (n = 99) (Fig. 6H,I). However, no data was available for miR-
371-3p and miR-372 with respect to overall patient survival. Therefore, we conclude that SMAR1 expression 
positively correlated with relapse free survival while miR-371 and miR-373 were predictors for poor prognosis. 
Taken together, SMAR1 curbs tumor formation, migration, invasion and metastasis through regulation of the 
miR-371-373 cluster (Fig. 6J).
Discussion
Cancer is a micro-evolutionary process resulting from changes in the epigenome, loss of tight and controlled 
gene orchestration leading to, aberrant gene expression. Mutation or loss of tumor suppressor genes has been 
found to be one of the major causes of cancer initiation and progression. SMAR1 being a nuclear matrix protein, 
has the potential to regulate other vital processes in the cell as well. SMAR1 and p53 have been shown to mediate 
gene regulation in a competitive as well as co-ordinated fashion6,26. The outcome of gene expression also varies in 
either of these situations. With this aim, we proceeded to identify novel gene targets of SMAR1 in presence and 
absence of p53, by a high throughput ChIP-sequencing approach. Analysis suggested that SMAR1 can bind to 
a distinct set of genes in the presence and absence of p53. It was also found that p53 competes with SMAR1 for 
gene promoter occupancy as well as gene regulation altering the expression pattern of their common downstream 
gene targets (T cell receptor alpha variable 21 (TRAV21); leukocyte immunoglobulin-like receptor, subfamily 
B (LILRB); Y RNA (non-coding); U6 (non-coding small nuclear RNA); Clathrin Interactor 1 (CLINT1), and 
miR-373). For the same reason, we could observe significantly more number of SMAR1 bound peaks in the 
absence of p53 (HCT116 p53−/− data set) than in the presence of p53. It is also notable to have identified two 
lncRNAs (RP11-271C24.2, RP11-419C23.1) as SMAR1 targets whose functions are still unexplored. The com-
petitive binding of SMAR1 and p53 is appreciable in both these lncRNA genes and their gene regulation studies 
will provide new insights. p53 competing protein (p53CP), recently identified and characterized as p51/p63, has 
been shown to compete for binding at the p53 consensus sequence, thus inhibiting the transactivation potential 
of p5333,34. In another case, the interaction of the transcription factor Ets1 with p53 is indispensable for the CBP/
p53 complex formation and stability and hence important for UV-responsive p53 transactivation in embryonic 
stem cells35. The overlapping of p53 (repressor) and hepatic nuclear factor 3 (HNF-3) (activator) binding sites in 
the alpha-fetoprotein (AFP) promoter results in competitive displacement of HNF-3 from this promoter36.
With respect to the distribution of SMAR1 peaks within the different gene components, it was found that 
SMAR1 binds within the gene body with higher affinity than to any other region of the gene. Studies from our 
lab suggest that proteins like SMAR1 that play a pivotal role in transcription-coupled alternate splicing of genes 
localise at the splice junctions in this manner. Hence, we speculate that SMAR1 has a major contribution in gene 
splicing and might be part of the splicing machinery of genes37. Also, the binding of proteins in the promoter 
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Figure 6. SMAR1 inhibits cancer cells in vitro and in vivo by regulating miR-371-373 cluster. (A) (i) In vitro 
wound healing assay in control and Adeno-SMAR1 transduced MDA-MB-231 cells showed reduced cell migration 
upon SMAR1 over expression. (ii) Graphical representation of the distance migrated (microns). (B) In vitro cell 
invasion assay performed in control MDA-MB-231 cells against different treatments of SMAR1 and miR-371-
373 overexpression and/or knockdown alone and in combination. (C) In vivo imaging showing reduction in lung 
metastasis in mice injected with Adeno-SM transduced MDA-MB-231/Luc cells as compared to the mice injected 
with control MDA-MB-231/Luc cells. (D) Hematoxylin and Eosin staining of the lung sections of control mice 
showing alveolar collapse. Lung sections of Adeno-SM treated mice showing normal lung and alveolar architecture. 
(E) Quantitative real time PCR analysis showing increase in SMAR1 levels in the lung tissues of Adeno-SM treated 
mice. (F) Quantitative real time PCR analysis showing reduction in the miR-371-373 transcript levels in the lung 
tissues of Adeno-SM treated mice. (G) Kaplan-Meier relapse free survival analysis for SMAR1 in 1660 breast 
cancer patients. Lower expression levels of SMAR1 correlated with poor survival (p value = 0.00043). (H) Overall 
survival analysis for miR-371-5p in 99 breast cancer patients using MIRUMIR prediction tool. Higher expression 
levels corresponded to poor prognosis of patients (p value = 0.0143). (I) Disease free survival analysis for miR-
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and 5′ regulatory elements of genes are of utmost significance. Introns play an important role in regulating gene 
expression in eukaryotes. Introns in plants have been reported to enhance gene expression38. In the case of human 
ubiquitin C gene, the 5′ UTR intron consists of a potent enhancer element that is critical for its transcription reg-
ulation39. Thus, existing literature in the field suggest potential role of SMAR1 in gene expression by binding to 
strong enhancer/regulatory elements of target genes. Binding sequence analysis of the SMAR1 target sequence 
reads identified T(C/G) repeat as the putative SMAR1 binding site in both the data sets irrespective of the sta-
tus of p53. As ChIP-seq does not predict direct binding, the predicted SMAR1 binding repeat was validated by 
EMSA and ITC experiments. Presence of such repeats has been shown to have a functional role in binding of 
transcription regulators. CA repeats are thought to be conserved even in evolutionarily distant organisms and are 
likely to confer a unique conformation to the DNA40,41. Further, these sequences are observed to undergo CpG 
methylation, thereby playing a crucial role in gene repression. Such stretches of alternating purine/pyrimidine 
repeats confer a Z-DNA conformation in vitro and they have been implicated in both structure and regulation 
of eukaryotic chromatin42,43. We speculate that the presence of such repetitive doublets in the binding sequence 
probably confers a unique conformation to the chromatin in that region, which defines the specificity and affinity 
of SMAR1 binding at such sequences. This observation fits well owing to the established role of SMAR1 to be a 
transcriptional repressor of genes.
miR-371-373 is upregulated in higher grades of cancers, promoting metastasis and tumorigenesis. 
β -catenin/LEF1 has been reported to transactivate this microRNA-371-373 cluster that in turn regulates the 
Wnt/β -catenin-signaling pathway44. Previous studies from our lab have shown that levels of SMAR1 drastically 
decrease as the cancer progresses5. Taking these facts into consideration, we hypothesized that SMAR1 might reg-
ulate this miRNA cluster thereby promoting metastasis upon SMAR1 knock down/absence. Endogenous SMAR1 
levels inversely correlate to the metastasis of the breast cancer lines, and thereby to all the microRNAs in the clus-
ter miR-371-373. Thus, as the levels of SMAR1 in the non-metastatic cell line MCF-7 increased, the expression 
of all these miR transcripts, and thereby the metastatic property of the cells decreased. Further, ChIP-PCR con-
firmed the occupancy of SMAR1 at the miR-371-373 locus, validating the ChIP-seq data and the role of SMAR1 
in its regulation. We identified the presence of repressor complex including HDAC1/mSin3A and H3K9me3 
histone mark at the promoter alongwith SMAR1 in HEK293 and MCF-7 cell lines. In MDA-MB-231 and T47D 
cells, an activator complex including RNA pol II and H3K9Ac activator histone mark were detected. SMAR1 
has been shown to promote ubiquitination and subsequent degradation of the histone acetyl transferase p30045. 
Therefore, we speculate that upon reduced endogenous levels of SMAR1, p300 might form a part of the activator 
complex inducing miR-371-373, as demonstrated by the presence of elevated H3K9Ac in such cells46. Real time 
PCR analysis of microRNAs upon SMAR1 overexpression and knock down reveals that SMAR1 negatively con-
trols the transcription of all the four microRNAs, namely, miR-371-3p, miR-371-5p, miR-372 and miR-373. Thus, 
we conclude that SMAR1 exerts a transcriptional control on the expression of this microRNA cluster.
miR-371-373 has been implicated as oncomiRs in several types of cancers. Voorhoeve et al. in 200647 reported 
that miR-371 and miR-372 act as oncogenes in testicular germ cell tumors. The over-expression of the miR-371 
cluster alone has been demonstrated to overcome cell cycle arrest following introduction of RASV12. Cellular 
transformation could be induced by the other two miRNAs in the cluster, miR-372 and miR-373 along with onco-
genic RAS and WTp53. miR-373 has been reported to stimulate cell proliferation in human esophageal cancer 
by post-transcriptionally regulating large tumor suppressor, homolog 2 (LATS2)48. It has also been proposed to 
function as an oncogene in hepatocellular carcinoma via regulation of protein phosphatase 649. An imprinted 
anti-miR-371-373 transcript, identified to act as an antisense regulator of onco-miR-372-3, functions as a tumor 
suppressor by cell growth arrest and apoptosis50. In pancreatic cancer patients, the increased expression levels 
of miR-371-5p were associated with significantly shorter survival and poor prognosis51. The overexpression of 
oncogenic miRNAs, miR-21, miR-10b, miR-155, miR-373 and miR-520c in breast cancers has been documented 
by many research groups. The mechanism by which miR-373 contributes to tumor progression and metastasis has 
been attributed to its ability of binding to the 3′ UTR of CD44 mRNA and repressing its translation. The outcome 
of this regulation is upregulated levels of miR-373 and reduced levels of CD44 in clinical breast carcinoma sam-
ples. Similar findings have been reported in the case of enhanced invasion of prostate cancer by miR-373 and 520c 
as well52. In the light of these reports, we were interested in deciphering the effect of SMAR1 on breast cancer pro-
gression and metastasis by regulating this miR-371-373 cluster. Our experiments highlight the role of SMAR1 in 
inhibiting cancer cell migration, invasion, cancer progression and metastasis by regulating this critical cluster of 
microRNAs. These findings unravel a new mechanism by which SMAR1 executes its tumor suppressor function.
In summary, we have identified the potential of SMAR1 as a global gene regulator and chromatin modifier, 
orchestrating the expression of varied genes, including microRNAs. This study opens new horizons in the less 
explored field of transcription control of a cluster of microRNAs and its implications in breast cancer progression.
Methods
Cell lines and cell culture. HEK293, MCF-7, HCT116 p53+/+ and HCT116 p53−/− cells were cultured in 
DMEM, T47D cells in RPMI, supplemented with 10% FBS and antibiotic and antimycotic (1X, Gibco) at 37 °C 
373 in 99 breast carcinoma patients using MIRUMIR tool. Higher expression levels led to decreased survival of 
patients (p value = 0.0181). (J) Model depicting the inhibition of tumor progression and metastasis by SMAR1 
mediated regulation of miR-371-373 cluster. Under normal scenario or in benign breast cancer, SMAR1 is present 
in physiologically normal levels in the cell thereby forming a repressor complex at the miR-371-373 promoter and 
repressing its expression. This allows the tumor suppressor mRNA targets of this cluster like LATS2 (Large Antigen 
Tumor Suppressor 2), CD44 to be translated preventing cellular transformation and maintaining homeostasis.
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with 5% CO2. MDA-MB-231 and MDA-MB-231/Luc cells were cultured in Leibovitz’s L-15 medium with 10% 
FBS and antibiotic and antimycotic (1X) at 37 °C. The cultured cells were used for further experiments.
Plasmids, transfections and transductions. The plasmids used for transfection experiment were pre-
pared by Qiagen Midiprep kit. Transfection was carried out using Lipofectamine-2000 in OptiMEM without FBS. 
Cells were transfected with SMAR1 knockdown construct (sh1077) and harvested at 60 hours and protein extrac-
tion or RNA extraction was done. pCMV-miR-371, pCMV-miR-372 and pCMV-miR-373 constructs (Origene) 
were used for respective microRNA overexpressions as described above. Replication deficient recombinant 
SMAR1 adenovirus (Adeno-SM) was propagated in HEK293T cells and transduced in desired cells for 72 hours.
Chromatin immunoprecipitation (ChIP). Chromatin immunoprecipitation (ChIP) was done using 
HCT116 p53+/+ and HCT116 p53−/− cells as described earlier4,6,37 using a chromatin immunoprecipitation 
(ChIP) assay kit (Upstate Biotechnology) following the manufacturer’s instructions. PCR was performed using 
different promoter specific primers.
Chromatin immunoprecipitation-sequencing (ChIP-seq) and in silico analysis. Chromatin immu-
noprecipitation (ChIP) was carried out using anti-SMAR1 antibody (Catalog no. A300-279A, Bethyl Laboratories, 
Inc., USA) and normal IgG control from HCT116 p53+/+ and HCT116 p53−/− cells as stated above. The eluted DNA 
fragments were subjected to single end sequencing using IlluminaGAIIx Analyzer as per manufacturer’s protocol. 
After adapter trimming using Cutadapt v1.2.153 and confirming thread quality using FastQCv0.10.1 program (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/), 14285728 and 25870976 good quality reads were obtained 
from HCT116 p53+/+ and HCT116 p53−/− pulldown samples, respectively. These reads were then aligned to the 
human reference genome (hg19 Build) downloaded from UCSC genome browser54 using Bowtie2 v2.2.1 program55. 
The resultant sequence alignment map (sam)  files were further converted to bam and bed format using SAMTools 
v0.1.1856. The bed files were used as the input to IGV2.3.2657 and MACS v1.4.258 for visualization of alignment and 
peak calling, respectively. The obtained peaks were filtered on the basis of fold enrichment values. The nucleotide 
sequences corresponding to the peak coordinates were downloaded from UCSC genome browser and used as input 
to MEME-ChIP v4.10.159 for motif analysis. The nearest downstream gene (NDG) function of PeakAnnotation 
option provided by PeakAnalyzer v1.460 was used to annotate peaks. HCT116 p53+/+ and HCT116 p53−/− data sets 
were then analyzed and compared for common and sample specific gene targets. The presence of the p53 consensus 
in the sequences corresponding to peaks was identified with the help of a custom Perl script. The gene ontology and 
pathway analysis were performed using DAVID Bioinformatics Resources 6.715.
Codes and softwares. All above softwares were downloaded as precompiled binaries and used on Linux 
platform. To handle sequencing data, finding consensus sequence and any for sort of automation, in-house cus-
tom Perl scripts were written and used. MAR-Wiz (http://genomecluster.secs.oakland.edu/MarWiz/) was used for 
determining MAR potential of the sequence of interest. The following sliding window parameters have been used: 
(i) Window width 1000; (ii) Slide distance 100; (iii) Cutoff threshold 0.60 and (iv) Run length 3.
RNA extraction and quantitative real time PCR. Total cellular RNA was extracted using TRIzol rea-
gent according to manufacturer’s (Sigma) protocol and first strand cDNA was synthesized from 2 μ g RNA. For 
quantitative analysis of SMAR1 expression, Real Time PCR was performed by StepOne™ Real-Time PCR System 
(Applied Biosystems). In a 10 μ l PCR reaction, cDNA was amplified using Power SYBR® Green PCR Master Mix 
(Applied Biosystems), 50 pmol of forward and reverse primer mix. Confirmation of single product was deter-
mined by melt curve analysis. Comparative Ct method was utilised to quantify fold increase of specific mRNA(s) 
over control, where target was normalized to the endogenous GAPDH reference. The cycle number from loga-
rithmic phase of the PCR curve where an increase in fluorescence was detected above background was recorded 
as the threshold Ct value. The Δ Ct was determined by subtracting the Ct value of GAPDH from that of target. The 
fold increase over control = 2−ΔΔCt where Δ Δ Ct = Δ Ct(control)− Δ Ct (treatment).
miRNA isolation and quantification. miRNA was isolated using mirVana miRNA Isolation Kit 
(Ambion). In brief, the cells were lysed in a denaturing buffer, RNA was extracted using acid phenol: chloroform, 
and the samples brought to 25% (v/v) ethanol were passed through a glass-fiber filter. The filtrate was passed 
through a second glass-fiber filter, washed and eluted in a low ionic strength solution. Quantitative real time PCR 
was performed as described above. The relative abundance of the specific miRNAs was normalized to U6snRNA.
Western blot analysis. SMAR1 and β -Actin protein levels were determined by immunoblotting. In brief, 
the proteins were extracted using protein extraction buffer (20 mM Tris-HCl pH-7.8, 1 mM EDTA, 1 mM PMSF, 
0.1% (v/v) Triton X-100, PI cocktail) and then quantified using Bradford’s reagent (Bio-Rad). Equal amount 
of protein was loaded on 10% SDS-PAGE and samples were electrotransferred to PVDF membrane at 100 V 
constant voltage. The blots were then saturated with 5% (w/v) BSA/3% (w/v) non-fat dry milk and reacted with 
respective primary antibodies, then incubated with secondary antibodies tagged with horseradish peroxidase. 
Signals were detected by chemiluminescence using luminol as a substrate (Thermo Scientific).
Electrophoretic mobility shift assay (EMSA). Cy5-tagged (both at 5′ and 3′ end) (TG)10 and (TC)10  
oligos were used in combination with other competitive untagged oligos (AT)10, (GC)10, (TCTG)5 and alterna-
tively with (TC)10 and (TG)10 oligos for repeat binding sequence confirmation. Purified recombinant SMAR1 pro-
tein with poly(dI-dC) [Poly(deoxyinosinic-deoxycytidylic), Sigma] (1 mg/ml) was incubated with the oligos alone 
or in different combinations, at room temperature for 1 hour in 50 mM Tris buffer (pH 7.5). The samples were then 
loaded on 8% native-PAGE pre-run at 100 V constant voltage at 4 °C for 1 hour and imaged in Typhoon FLA 9500 
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(GE Healthcare). PCR amplicon of miR-371-373 upstream MAR region was column purified and incubated with 
increasing concentrations of the purified recombinant SMAR1 protein and poly(dI-dC) for 1 hour at 37 °C. The 
sample was then loaded and resolved on a similar pre-run 10% native-PAGE at 4 °C. The gel was then stained with 
0.5 μ g/ml ethidium bromide, rinsed with water and visualized (Versadoc, Bio-Rad).
Isothermal titration calorimetry (ITC). The sample cell and Hamilton syringe were rinsed with water 
followed by buffer washes. The experimental parameters of the reaction carried out in MicroCalTM iTC200 system 
(GE Healthcare) are: Total injections: 19; Cell temperature: 25°; Reference power (μ cal/sec): 10; Initial delay (sec): 
60; Stirring speed (rpm): 1000. Injection of 0.4 μ l (duration 0.8 sec) was followed by 18 injections of 2.0 μ l (dura-
tion 4 sec) with 150 seconds between injections. The purified recombinant SMAR1 protein (the macromolecule) 
was titrated against oligo sequence [(TG)10 or (TC)10] (the ligand). Data analysis was done using the MicroCal 
Analysis Launcher software.
Luciferase reporter assay. To generate the SMAR1 binding site deletion mutant, PCR based site-directed 
mutagenesis was performed as described by Nassal and Rieger, 199061. The ChIP-seq predicted SMAR1 peak in 
the promoter of miR-371-373 cluster was PCR amplified from genomic DNA using promoter-specific primers 
and cloned in pGL4.17[luc2/Neo] vector, referred to as pluc371 construct in this study. The MAR-deleted pro-
moter was cloned using primers with compatible restriction site overhangs in pGL4.17 [luc2/Neo] vector, referred 
as pluc371Δ MAR construct. Cells were treated with control, Adeno-SM and sh1077 in combination with pluc371 
or pluc371Δ MAR constructs and luciferase activities were measured after 60 hours of transfection by using the 
Dual Luciferase assay kit (Promega). pRL Renilla luciferase control reporter vector was used as internal control. 
The results were normalized to Renilla luciferase activity using Fluoroskan Ascent Luminometer (Lab Systems).
Migration and invasion assays. A 10 μ l pipette tip was used to generate an artificial wound onto confluent 
cell monolayers of control or Adeno-SM transduced MDA-MB-231 cells. The cell migration was then observed 
in serum containing medium upto 24 hours of the above mentioned treatments(s). Images were taken at 37 °C 
using Motorized IX-81 inverted microscope attached with DP70 CCD camera (Nikon). The distance migrated 
towards the wound was calculated after 90 minutes. MDA-MB-231 cells, alone or overexpressed with differ-
ent pCMV-miR constructs or knocked down using antagomiRs in combination with SMAR1 over expression 
(Adeno-SM) or SMAR1 knockdown (sh1077 construct) were added to the upper chamber of the Boyden chamber 
(Corning). AntagomiRs used in the assay were anti-miR-371-3p, anti-miR-371-5p, anti-miR-372, anti-miR-373 
and anti-miR-negative control (Ambion). The cells migrated to the reverse side of the upper chamber were fixed 
and stained with Crystal violet and counted under an inverted microscope (Nikon). Data are represented as the 
average of five fields per treatment well.
In vivo tumorigenicity and imaging. All mice used in the animal experiments were bred at animal 
resource facility of National Centre for Cell Science (NCCS), Pune, India. All experiments were performed using 
standard protocols approved and monitored by institutional animal ethical committee of NCCS. All the methods 
were carried out in accordance with the approved guidelines of the animal ethical committee of NCCS. 106 con-
trol and Adeno-SM transduced MDA-MB-231/Luc cells in sterile 1X PBS were injected into SCID mice via tail 
vein. The injected cells were then observed for their localization and/or metastasis by in vivo imaging. For this 
purpose, the mice were anesthetized, injected with luciferin (PerkinElmer) substrate (3 mg/20 g mice) and visu-
alized under the in vivo imaging system (Xenogen). The mice were sacrificed and its vital organs were collected. 
Part of organs fixed in 10% (v/v) formalin was processed for Hematoxylin and Eosin staining (5 μ m thickness) 
and imaged (Nikon). The remaining organ parts were used for total RNA and miRNA isolation.
Survival curve analysis. Correlation of relapse free survival of breast cancer patients (n = 1660) with 
SMAR1 gene expression was analyzed using Kaplan-Meier Plotter with JetSet best probe set (http://kmplot.com/
analysis/)30,62. Correlation of survival of breast cancer patients (n = 99) with hsa-miR-371-5p and hsa-miR-373 
was performed using MIRUMIR online survival analysis tool (http://www.bioprofiling.de/MIRUMIR)31,32.
Statistical analysis. All the experiments were performed at least thrice and the data are expressed as 
mean ± standard deviation. Statistical significance was calculated using either Student’s t-test or one-way 
ANOVA with a subsequent post hoc Tukey’s test for multiple comparisons. The significance values are defined as 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001 for ANOVA and #p ≤ 0.05, ##p ≤ 0.005 for Student’s t-test. 
Densitometry analysis was done using the NIH ImageJ software (https://imagej.nih.gov/ij/).
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